Prostate Cancer Drugs Promise Longer Life — What's the Catch?
New cancer drug combinations offer hope. Targeting enzymes could weaken prostate cancer cells. This may help men with advanced disease live longer.
Experts reveal a key to this treatment. Niraparib and abiraterone acetate plus prednisone show promise. They are used for a specific type of prostate cancer. This includes metastatic castration-sensitive prostate cancer.
A phase 3 trial tested these drugs. The combination significantly boosted progression-free survival. This means patients lived longer without their cancer worsening.
The findings are significant for many patients. Further research is needed to see how widely these treatments will be adopted.
